GlassScriptPhysician profile
Jill D Broffman
NPI 1609800630
$3,913.06
in general payments reported to CMS, 2019-2025
26 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $61.77 · 2021: $60.48 · 2022: $1,700 · 2023: $100 · 2024: $569 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,685.70 | 2022 | |
| Abbvie INC. | $439.29 | 2021-2025 | |
| Lilly USA, LLC | $213.18 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Pfizer INC. | $200.67 | 2019-2025 | |
| Amgen INC. | $171.53 | 2025 | Otezla, Repatha |
| Sk Life Science, INC. | $168.55 | 2024-2025 | |
| Nevro Corp. | $123.28 | 2019 | |
| Exact Sciences Corporation | $114.52 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $111.88 | 2024-2025 | Breztri, Airsupra |
| Neurelis, INC. | $89.78 | 2024-2025 | Valtoco |
| Eisai INC. | $72.86 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.24 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.17 | 2019-2020 | |
| Ge Healthcare | $54.61 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.38 | 2020-2024 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $40.33 | 2019-2023 | Wegovy |
| Mallinckrodt Enterprises LLC | $32.03 | 2019 | |
| Genentech USA, INC. | $28.77 | 2024 | Ocrevus |
| Abbott Laboratories | $28.40 | 2025 | Infinity |
| Lundbeck LLC | $27.17 | 2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $26.98 | 2025 | Crexont |
| Acadia Pharmaceuticals INC | $26.74 | 2025 | Nuplazid |
| Tanabe Pharma America, INC. | $25.11 | 2025 | Radicava |
| Grifols USA, LLC | $24.13 | 2024 | Gamunex-C |
| Tonix Medicines, INC. | $16.66 | 2025 | Zembrace Symtouch |
| Merck Sharp & Dohme LLC | $14.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Broffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.